Published in N Engl J Med on August 31, 2013
Dabigatran Etexilate in Patients With Mechanical Heart Valves (RE-ALIGN) | NCT01452347
Follow on Study From RE-ALIGN | NCT01505881
Genotype-guided Warfarin Individualized Treatment | NCT02211326
Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48
Direct oral anticoagulants: integration into clinical practice. Postgrad Med J (2014) 1.40
Approach to the new oral anticoagulants in family practice: part 1: comparing the options. Can Fam Physician (2014) 1.07
Dabigatran versus warfarin in patients with mechanical heart valves: comment. J Thromb Haemost (2014) 1.06
Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc (2014) 1.00
2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. J Thorac Cardiovasc Surg (2014) 0.99
Factor XI and contact activation as targets for antithrombotic therapy. J Thromb Haemost (2015) 0.94
Anticoagulation in atrial fibrillation. BMJ (2014) 0.93
Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012. Am Heart J (2014) 0.92
Self-management of oral anticoagulation. Dtsch Arztebl Int (2014) 0.91
Successful resolution of a left ventricular thrombus with apixaban treatment following acute myocardial infarction. Heart Vessels (2014) 0.91
New oral anticoagulants for atrial fibrillation: are they worth the risk? P T (2014) 0.87
Dabigatran in patients with mechanical heart valves. N Engl J Med (2014) 0.87
A new era of stroke prevention in atrial fibrillation: comparing a new generation of oral anticoagulants with warfarin. Int Arch Med (2013) 0.86
Dabigatran in patients with mechanical heart valves. N Engl J Med (2014) 0.86
Dabigatran in patients with mechanical heart valves. N Engl J Med (2014) 0.86
Future prospects for contact factors as therapeutic targets. Hematology Am Soc Hematol Educ Program (2014) 0.85
Dabigatran in patients with mechanical heart valves. N Engl J Med (2014) 0.85
Anticoagulation in patients with mechanical heart valves: follow the guidelines! Neth Heart J (2015) 0.85
Dabigatran in patients with mechanical heart valves. N Engl J Med (2014) 0.85
New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag (2015) 0.84
Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence. Adv Hematol (2015) 0.84
Anticoagulation for prosthetic valves. Thrombosis (2013) 0.83
New oral anticoagulants and the cancer patient. Oncologist (2013) 0.83
Left atrial appendage closure in a patient with atrial fibrillation after mechanical mitral valve replacement and cardio-embolic stroke despite effective oral anticoagulant therapy: a case report. Clin Res Cardiol (2014) 0.82
Dabigatran and mechanical heart valves--not as easy as we hoped. N Engl J Med (2013) 0.82
Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association. Circulation (2017) 0.82
Pregnancy complicated by valvular heart disease: an update. J Am Heart Assoc (2014) 0.81
Doubly blind: a systematic review of gender in randomised controlled trials. Glob Health Action (2016) 0.80
Sex differences in treatment quality of self-managed oral anticoagulant therapy: 6,900 patient-years of follow-up. PLoS One (2014) 0.80
Expanding use of new oral anticoagulants. F1000Prime Rep (2014) 0.80
Secondary stroke prevention: challenges and solutions. Vasc Health Risk Manag (2015) 0.79
Evaluation of dabigatran for appropriateness of use and bleeding events in a community hospital setting. Am Health Drug Benefits (2014) 0.79
Left atrial thrombus formation and resolution during dabigatran therapy: A Japanese Heart Rhythm Society report. J Arrhythm (2015) 0.78
Dabigatran use in mechanical heart valve patients. Future Cardiol (2014) 0.78
Dabigatran versus warfarin after bioprosthesis valve replacement for the management of atrial fibrillation postoperatively: protocol. JMIR Res Protoc (2014) 0.78
Horseshoe thrombus in a patient with mechanical prosthetic mitral valve: A case report and review of literature. World J Clin Cases (2015) 0.78
Dental Procedures in Patients with Atrial Fibrillation and New Oral Anticoagulants. Arrhythm Electrophysiol Rev (2014) 0.78
Meta-analysis of Randomized Controlled Trials of Genotype-Guided vs Standard Dosing of Warfarin. Chest (2015) 0.78
Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation. Vasc Health Risk Manag (2015) 0.77
New oral anticoagulants: are coagulation units still required? Thromb J (2014) 0.77
Influence of genetic polymorphisms in cytochrome P450 oxidoreductase on the variability in stable warfarin maintenance dose in Han Chinese. Eur J Clin Pharmacol (2016) 0.76
Practical and clinical considerations in assessing patients with atrial fibrillation for switching to non-vitamin K antagonist oral anticoagulants in primary care. Int J Gen Med (2015) 0.76
In situ regeneration of bioactive coatings enabled by an evolved Staphylococcus aureus sortase A. Nat Commun (2016) 0.76
Atrial fibrillation: a review of recent studies with a focus on those from the duke clinical research institute. Scientifica (Cairo) (2014) 0.76
Dabigatran is Less Effective Than Warfarin at Attenuating Mechanical Heart Valve-Induced Thrombin Generation. J Am Heart Assoc (2015) 0.76
Evolving cardiovascular uses of direct-acting oral anticoagulants: a paradigm shift on the horizon? Intern Emerg Med (2017) 0.76
A Case with Recurrent Free-Floating Ball Thrombi in Left Atrium. Am J Case Rep (2017) 0.75
Factors XI and XII as Targets for New Anticoagulants. Front Med (Lausanne) (2017) 0.75
Dabigatran-Associated Intracranial Hemorrhage: Literature Review and Institutional Experience. Neurohospitalist (2015) 0.75
Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol. BMJ Open (2016) 0.75
Does a complex intervention increase patient knowledge about oral anticoagulation? - a cluster-randomised controlled trial. BMC Fam Pract (2017) 0.75
Stroke prevention in atrial fibrillation: Commentary regarding the AAN's evidence-based guideline update. Neurol Clin Pract (2014) 0.75
Cardioembolic Stroke. Circ Res (2017) 0.75
Dabigatran versus warfarin in patients with mechanical heart valves: reply. J Thromb Haemost (2014) 0.75
VAD therapy 20/20: moving beyond the myopic view of a nascent therapy. Ann Cardiothorac Surg (2014) 0.75
Novel anticoagulants in patients with mechanical heart valves. Evid Based Med (2014) 0.75
Perioperative management of oral anticoagulants: a focus on target-specific oral anticoagulants. Hosp Pract (1995) (2014) 0.75
Clinical and genetic factors associated with warfarin maintenance dose in northern Chinese patients with mechanical heart valve replacement. Medicine (Baltimore) (2017) 0.75
[Dabigatran versus warfarin in patients with mechanical heart valves]. Rev Clin Esp (Barc) (2014) 0.75
Review of the top 5 cardiology studies of 2013-14. Can Pharm J (Ott) (2015) 0.75
Stroke Prevention in Atrial Fibrillation and Valvular Heart Disease. Open Cardiovasc Med J (2016) 0.75
Anticoagulation Quality and Complications of using Vitamin K Antagonists in the Cardiac Surgery Outpatient Clinic. Braz J Cardiovasc Surg (2016) 0.75
Dabigatran for mechanical valves. Hosp Pharm (2014) 0.75
Selecting antithrombotic therapy for patients with atrial fibrillation. Cleve Clin J Med (2015) 0.75
Dabigatran Versus Warfarin After Bioprosthesis Valve Replacement for the Management of Atrial Fibrillation Postoperatively: DAWA Pilot Study. Drugs R D (2016) 0.75
Incidence and predictors of excessive warfarin anticoagulation in patients with atrial fibrillation-The EWA study. PLoS One (2017) 0.75
Safety and Use of Anticoagulation After Aortic Valve Replacement With Bioprostheses: A Meta-Analysis. Circ Cardiovasc Qual Outcomes (2016) 0.75
Resolution of massive left atrial appendage thrombi with rivaroxaban before balloon mitral commissurotomy in severe mitral stenosis: A case report and literature review. Medicine (Baltimore) (2016) 0.75
Bleeding in continuous flow left ventricular assist device recipients: an acquired vasculopathy? J Thorac Dis (2016) 0.75
Perioperative Management of Direct Oral Anticoagulants (DOACs): A Systemic Review. Health Serv Insights (2016) 0.75
Potential new uses of non-vitamin K antagonist oral anticoagulants to treat and prevent stroke. Neurology (2015) 0.75
Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. J Thromb Thrombolysis (2016) 0.75
Utilization of Dabigatran for Atrial Fibrillation at 3 Tertiary Care Centres. Can J Hosp Pharm (2015) 0.75
Fibrinolytic Treatment after Transient Ischaemic Attack Caused by Prosthetic Mitral Valve Thrombosis. Case Rep Cardiol (2016) 0.75
Theme 3: Non-invasive management of (recurrent) venous thromboembolism (VTE) and post thrombotic syndrome (PTS). Thromb Res (2015) 0.75
Warfarin related nephropathy: a case report and review of the literature. BMC Nephrol (2016) 0.75
Anticoagulation therapy: Results of RE-ALIGN disappoint. Nat Rev Cardiol (2013) 0.75
Anticoagulation for the acute management of ischemic stroke. Yale J Biol Med (2014) 0.75
Dabigatran in patients with mechanical heart valves. N Engl J Med (2014) 0.75
Periprocedural antithrombotic therapy during various types of percutaneous cardiovascular interventions. Eur Heart J Cardiovasc Pharmacother (2015) 0.75
Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy. Ann Pharmacother (2016) 0.75
ACP Journal Club. Dabigatran increased bleeding and stroke compared with warfarin after mechanical heart valve implantation. Ann Intern Med (2013) 0.75
Highlights from the Ninth International Symposium of Thrombosis and Anticoagulation (ISTA IX), October 15, 2016, Salvador, Bahia, Brazil. J Thromb Thrombolysis (2017) 0.75
Increased Thromboembolic Events With Dabigatran Compared With Vitamin K Antagonism in Left Ventricular Assist Device Patients: A Randomized Controlled Pilot Trial. Circ Heart Fail (2017) 0.75
2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. J Arrhythm (2017) 0.75
Resumption of Anticoagulation After Intracranial Hemorrhage. Curr Treat Options Neurol (2017) 0.75
Efficacy and safety of novel oral anticoagulants in patients with bioprosthetic valves. Clin Res Cardiol (2015) 0.75
Potential use of NOACs in developing countries: pros and cons. Eur J Clin Pharmacol (2014) 0.75
A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science (2007) 18.96
Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med (2009) 17.17
Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med (2011) 15.70
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Universal definition of myocardial infarction. Circulation (2007) 11.69
Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med (2009) 11.49
Subclinical atrial fibrillation and the risk of stroke. N Engl J Med (2012) 11.11
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57
Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med (2004) 10.02
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 9.98
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54
Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med (2009) 8.51
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2012) 7.94
Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet (2006) 7.33
A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA (2004) 7.32
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2012) 6.94
Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med (2005) 6.86
Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet (2009) 6.83
The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet (2008) 6.72
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med (2013) 6.71
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48
Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med (2008) 6.17
Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA (2007) 6.06
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med (2010) 6.05
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med (2013) 6.01
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med (2007) 5.78
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA (2006) 5.74
Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. N Engl J Med (2015) 5.31
Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med (2006) 5.24
Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery. N Engl J Med (2009) 5.19
Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA (2004) 5.11
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet (2002) 5.04
Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med (2009) 4.83
Surgical ablation of atrial fibrillation during mitral-valve surgery. N Engl J Med (2015) 4.77
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol (2007) 4.74
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med (2010) 4.73
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med (2015) 4.50
Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol (2005) 4.40
Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation (2003) 4.36
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation (2012) 4.33
Soluble CD40 ligand in acute coronary syndromes. N Engl J Med (2003) 4.06
Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery. JAMA (2011) 3.97
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation (2006) 3.85
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation (2013) 3.73
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med (2008) 3.68
Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet (2005) 3.67
Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation (2007) 3.62
The second Euro Heart Survey on acute coronary syndromes: Characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. Eur Heart J (2006) 3.62
Acute myocardial infarction. Lancet (2003) 3.59
Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. Circulation (2009) 3.50
Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA (2007) 3.48
Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy. N Engl J Med (2015) 3.37
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J (2002) 3.36
Newly identified events in the RE-LY trial. N Engl J Med (2010) 3.35
Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart J (2011) 3.29
Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol (2010) 3.26
Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation (2013) 3.25
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med (2011) 3.20
Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study. Eur Heart J (2006) 3.14
Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J (2005) 3.09
Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography. Eur J Echocardiogr (2011) 3.07
Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke (2012) 3.02
Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. N Engl J Med (2002) 3.01
Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography. J Am Soc Echocardiogr (2011) 2.97
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation (2007) 2.95
Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J (2012) 2.94
Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med (2014) 2.90
N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol (2013) 2.90
Emergency department bypass for ST-Segment-elevation myocardial infarction patients identified with a prehospital electrocardiogram: a report from the American Heart Association Mission: Lifeline program. Circulation (2013) 2.85
Extent of, and factors associated with, delay to hospital presentation in patients with acute coronary disease (the GRACE registry). Am J Cardiol (2002) 2.82
Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med (2004) 2.80
Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet (2009) 2.79
Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol (2012) 2.78
Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation (2005) 2.78